Key result
Intracoronary bone marrow cell infusion fails to sustain LVEF improvement at 5 years in STEMI.
Why the study?
Whether a single intracoronary infusion of autologous BMCs can have a sustained long-term impact on LVEF in patients after STEMI required evaluation.
Does a single intracoronary infusion of autologous bone marrow cells promote a sustained improvement in left ventricular ejection fraction at 5 years in patients with ST-elevation myocardial infarction after successful percutaneous coronary intervention?
RCT (n=60)
Randomized
Does a single intracoronary infusion of autologous bone marrow cells promote a sustained improvement in left ventricular ejection fraction at 5 years in patients with ST-elevation myocardial infarction after successful percutaneous coronary intervention?
A single intracoronary infusion of autologous bone marrow cells does not sustain initial improvements in left ventricular ejection fraction at 5 years in patients with STEMI and relatively preserved systolic function.
Answers are grounded in this paper and cite their sources.
No sustained LVEF benefit from single bone marrow cell infusion post-STEMI; leaves open questions on subgroups or repeated dosing for future trials.
AIMS: We assessed whether a single intracoronary infusion of autologous bone marrow cells (BMCs) can have a sustained impact on left ventricular ejection fraction (LVEF) in patients after ST-elevation myocardial infarction (STEMI). In the BOne marrOw transfer to enhance ST-elevation infarct regeneration (BOOST) trial, 60 patients with STEMI and successful percutaneous coronary intervention were randomized to a control and a cell therapy group. As previously reported, BMC transfer led to an improvement of LVEF by 6.0% at 6 months (P = 0.003) and 2.8% at 18 months (P = 0.27). METHODS AND RESULTS: Left ventricular ejection fraction and clinical status were re-assessed in all surviving patients after 61 +/- 11 months. Major adverse cardiac events occurred with similar frequency in both groups. When compared with baseline, LVEF assessed by magnetic resonance imaging at 61 months decreased by 3.3 +/- 9.5% in the control group and by 2.5 +/- 11.9% in the BMC group (P = 0.30). Patients with an infarct transmurality > median appeared to benefit from BMC transfer throughout the 61-month study period (P = 0.040). CONCLUSION: A single intracoronary application of BMCs does not promote a sustained improvement of LVEF in STEMI patients with relatively preserved systolic function. It is conceivable that a subgroup of patients with more transmural infarcts may derive a sustained benefit from BMC therapy. However, this needs to be tested prospectively in a randomized trial.
No takes yet. Share an insight, caveat, or question.
MEYER et al. (2009) conducted an RCT in ST-elevation myocardial infarction (STEMI) (n=60). Intracoronary infusion of autologous bone marrow cells (BMCs) vs. Control group was evaluated on Change in left ventricular ejection fraction (LVEF) from baseline to 61 months (p=0.30).
Synapse has enriched 10 related papers. Consider them for comparative context: